WC3 reassortant vaccines in children
Bovine rotavirus strain WC3 (P7, G6) administered at the 12th passage level was well tolerated clinically in infants and efficiently induced serum virus neutralizing antibody (VNA) with bovine rotavirus G6 specificity. The protective efficacy of WC3 vaccine against all rotavirus disease was inconsistent, varying in four separate trials from 76% to 0%; some selective protection against severe disease was seen in all trials. WC3 reassortants containing the gene for an individual human rotavirus VP7 (G) or VP4 (P) surface antigen were also well tolerated, but preferentially induced VNA to the WC3 parent. Efficacy trials of human G1 VP7 reassortant WI79-9 (P7, G1) consistently led to >60% protection against all rotavirus disease. A quadrivalent WC3 reassortant vaccine was developed to contain four separate monovalent reassortants expressing human rotaviruses surface proteins G1, G2, G3, and P1A  respectively. In a multicenter trial including 439 infants, this vaccine induced 67.1% protection against all rotavirus disease (defined as positive for rotavirus antigen by ELISA only [p= <0.001]) and 72.6% protection when the standard for rotavirus diagnosis was a positive test of stool for both rotavirus antigen by ELISA and rotavirus RNA by electropherotype analysis (p = < 0.001). In this trial, episodes of the most severe rotavirus disease (clinical severity score > 16.0, eight cases) occurred only in placebo recipients.
KeywordsVirus Neutralize Antibody Reassortant Vaccine Virus Neutralize Antibody Response 12th Passage Level Rota Virus Vaccine
Unable to display preview. Download preview PDF.
- 6.Clark HF, Furukawa T, Bell LM, Offit PA, Perrella PA, Plotkin SA (1986) Immune response of infants and children to low-passage bovine rotavirus (strain WC3). Amer J Dis Children 140: 350–356Google Scholar
- 10.Clark HF, Offit PA (1994) Rotavirus vaccines. In: Plotkin SA, Mortimer EA (eds) Vaccines. Saunders, Philadelphia, pp 809–822Google Scholar
- 11.Clark HF, Welsko D, Offit PA (1992) Infant responses to bovine WC3 reassortants containing human rotavirus VP7, VP4, or VP7 & VP4. ICAAC Anaheim, p 343Google Scholar
- 12.Clark HF, White CJ, Offit PA, Stinson D, Eiden J, Weaver S, Cho I, Shaw A, Krah D, Ellis R + OHBRV Study Group (1995) Preliminary evaluation of safety and efficacy of quadrivalent human-bovine reassortant rotavirus vaccine. Ped Res 37: 172AGoogle Scholar
- 14.Estes MK, Graham DY, Petrie BL (1985) Antigenic structure of rotaviruses. In: van Regenmortel MHV, Neurath AR (eds) Immunochemistry of viruses. Elsevier, Amsterdam, pp 389–405Google Scholar
- 15.Estes MK (1996) Rotaviruses and their replication. In: Fields BN et al. (eds) Virology. Lippincott-Raven Publishers, New York, pp 1625–1655Google Scholar
- 17.Georges-Courbot MC, Monges J, Siopathis MR, Roungou JP, Gresenguet G, Bellec L, Bouquety JC, Lanckviet C, Cadoz M, Hessel L, Gouvea G, Clark HF, Georges AJ (1991) Evaluation of the efficacy of a low passage bovine rotavirus (strain WC3) vaccine in children in Central Africa. Res Virol 142: 405–411PubMedCrossRefGoogle Scholar
- 19.Institute of Medicine (1986) The prospects for immunzing against rotavirus. In: New vaccine development. Establishing priorities. Diseases of importance in developing countries, vol II. National Academy Press, Washington, DC, pp 308–318Google Scholar
- 21.Mebus CA, Underdahl NR, Rhodes MB, Twiehaus MJ (1969) Calf diarrhea (Scours): reproduced with a virus from a field outbreak. Nebraska Res Bull 233. Nebraska Agricultural Experiment Station, Lincoln, NebraskaGoogle Scholar
- 22.Mebus CA, White RG, Stair FL, Rhodes MB, Twiehaus MJ (1972) Neonatal calf diarrhea: results of a field trial using a reo-like virus vaccine. Vet Med Ann Clin 67: 173–174Google Scholar